Literature DB >> 2497014

In vitro and in vivo evaluation of antifungal agents.

A Espinel-Ingroff1, S Shadomy.   

Abstract

The evaluation of any antifungal agent involves the determination of its in vitro and in vivo activity against pathogenic and/or opportunistic fungi. The in vitro evaluation is followed by an in vivo evaluation in animal models, and clinical trials in humans. From the first report of the efficacy of the iodides for the treatment of sporotrichosis (1903) until the introduction of the imidazoles (azoles, 1960s), the number of antifungal agents available was very limited, including griseofulvin (1939), nystatin (1950), amphotericin B (1956), and flucytosine (1964). This paper briefly reviews the status of the antifungal agents currently used, and gives a more in depth evaluation of progress during recent years in the search for new antifungal drugs. Efforts to improve the efficacy of the current antifungal agents are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2497014     DOI: 10.1007/bf01963469

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  77 in total

1.  Toxicity of intravitreal injection of fluconazole in the rabbit.

Authors:  J A Schulman; G Peyman; R Fiscella; G Small; M Coats; C P Wajszczuk; L Steahly
Journal:  Can J Ophthalmol       Date:  1987-10       Impact factor: 1.882

2.  Enhanced efficacy of amphotericin B and rifampicin combined in treatment of murine histoplasmosis and blastomycosis.

Authors:  M Kitahara; G S Kobayashi; G Medoff
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria.

Authors:  R A Woods; M Bard; I E Jackson; D J Drutz
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections.

Authors:  R C Heel; R N Brogden; A Carmine; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

6.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

Authors:  M A Burgess; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

8.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

9.  R 51211 (itraconazole) therapy of murine cryptococcosis.

Authors:  J R Graybill; J Ahrens
Journal:  Sabouraudia       Date:  1984

10.  Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents.

Authors:  U Ganzinger; A Stutz; G Petranyi; A Stephen
Journal:  Acta Derm Venereol Suppl (Stockh)       Date:  1986
View more
  12 in total

1.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Fluconazole therapy in an underweight infant.

Authors:  C Viscoli; E Castagnola; M Corsini; R Gastaldi; M Soliani; A Terragna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

3.  Evaluation of five commercial antifungal susceptibility testing systems.

Authors:  A Druetta; A Freydiere; R Guinet; Y Gille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

4.  Effects of temperature on anti-Candida activities of antifungal antibiotics.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Comparative efficacy of amphotericin B, clotrimazole and itraconazole against Aspergillus spp. An in vitro study.

Authors:  Y H Hahn; D G Ahearn; L A Wilson
Journal:  Mycopathologia       Date:  1993-09       Impact factor: 2.574

6.  Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.

Authors:  C Quereda; A M Polanco; C Giner; A Sánchez-Sousa; E Pereira; E Navas; J Fortún; A Guerrero; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

7.  Effects of ranitidine and sucralfate on ketoconazole bioavailability.

Authors:  S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  Comparison study of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; T M Kerkering; P R Goldson; S Shadomy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.